AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

This morning, pharma major AbbVie and fellow USA-based EvolveImmune Therapeutics announced the signing of a collaboration and ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

AbbVie is strengthening its neurology portfolio with a $1.4 billion acquisition of Aliada Therapeutics. The North Chicago-based drugmaker said in a statement this morning that Aliada has a blood ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Chicago, IL – November 8, 2024 – Today, Zacks Investment Ideas feature highlights AbbVie ABBV, Visa V and Comfort Systems USA ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Charting, Price Performance, News & Related Contracts.

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct. 15th. While investors will wait to hear about quarterly earnings on ...

AbbVie also said that the drug provided more ... and dyskinesia. Download USA TODAY's app to get to the heart of news FDA approves the first at-home test for COVID-19 and the flu, no prescription ...